Deans' stroke musings: Sygnis Pharma AG has completed patient recruitment for its AXIS 2 Study

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, August 9, 2011

Sygnis Pharma AG has completed patient recruitment for its AXIS 2 Study

I had to google AX200 to barely come up with what this drug is trying to do.
Filgrastim is a granulocyte colony-stimulating factor (G-CSF) analog used to stimulate the proliferation and differentiation of granulocytes.^{[1] see wikipedia for more}. Even following definitions down a few levels I still have no idea what possible use this is for. But hey you can volunteer for the study. Good luck
http://www.dddmag.com/Sygnis-Pharma-Completes-Patient-Recruitment-080911.aspx
Sygnis Pharma Completes Patient Recruitment
Drug Discovery & Development - August 09, 2011

Sygnis Pharma AG has completed patient recruitment for its AXIS 2 Study, a randomized, double-blind study designed to demonstrate the efficacy of AX200 (G-CSF) for the treatment of patients with acute ischemic stroke.

“With the completion of patient enrolment we have reached the next milestone of the clinical development of AX200 for the treatment of acute stroke. After the completion of a 3 month monitoring period of this last patient, we will enter the crucial evaluation phase during which we will analyse all collected data and, as a result, gain clarity on the potential of AX200 for the treatment of acute stroke,” says Frank Rathgeb, MD, chief medical officer of Sygnis.

Based on these findings, Sygnis will evaluate the options for the further development or commercialization of AX200. The company may start an additional clinical study to confirm the efficacy of AX200 for the treatment of acute stroke by itself or with an appropriate pharma partner, or it may out-license the AX200 project.

Its recruiting here:

http://clinicaltrials.gov/ct2/show/NCT00927836?term=ax200&rank=2

Maybe this line is the answer;

Filgrastim is also used to increase the number of hematopoietic stem cells in the blood before collection by leukapheresis for use in hematopoietic stem cell transplantation. It is produced by many companies worldwide.